Accessibility Menu
Immuneering logo

Immuneering(NASDAQ) IMRX

Market Cap$284.02MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2021)-75%
5 Year-84%
1 Year+23%
1 Month-15%
$4.48
+1.94%
+0.08Today
After hours$4.46-$0.01 (-0.34%)
Immuneering last closing stock price
MetricPriceDate
Last closeUSD 4.392026-08-05
Immuneering stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+8.26%USD 4.062026-07-29
1 month-14.59%USD 5.142026-07-06
3 month-15.9%USD 5.222026-05-07
Year to date-33.28%USD 6.582025-12-31
1 year+22.97%USD 3.572025-08-05
3 year-57.95%USD 10.442023-08-04
5 year-84.45%USD 28.232021-08-06
Since inception-75.04%USD 17.592021-07-30

Immuneering Financials at a Glance

Market Cap

$284.02MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$360.96K

Net Income (TTM)

-$57.28M

EPS (TTM)

-$1.17

P/E Ratio

-3.77

Dividend

$0.00

Beta (Volatility)

1.33 (Average)

Price

$4.48

Volume

768,572

Open

$4.64

Previous Close

$4.46

Daily Range

$4.35 - $4.72

52-Week Range

$2.90 - $10.08

Estimated Earnings Date

Aug 12, 2026

IMRX News

Foolcom-Featured.png

Immuneering Posts Narrower Loss in Q2

Motley Fool Markets TeamAug 13, 2025
healthcare lab treatment research scientist

Why Shares of Immuneering Jumped This Week

James HalleyMar 24, 2023

IMRX: Motley Fool Moneyball Superscore

63

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Immuneering

Immuneering makes new medicines to help people with cancer live longer. These drugs aim to kill tumors without hurting healthy body parts. The company focuses on treating hard-to-hit cancers like pancreatic cancer.

Fighting Cancer with Smart Cycles

  • Atebimetinib: Oral drug designed to treat pancreatic and lung cancers by hitting specific growth signals in the body.
  • Envometinib: Secondary clinical candidate targeting solid tumors with specific genetic mutations; internal development is currently paused.
  • DCI Platform: Proprietary technology using computer analysis and 3D models to find and test new drug targets.

Strategic Deals and Decisions

  • Announced a clinical supply agreement with Regeneron Pharmaceuticals in February 2025 to test drug combinations in lung cancer.
  • Signed a deal with Eli Lilly and Company in August 2025 for a combination study in non-small cell lung cancer.
  • Received Fast Track and Orphan Drug designations from federal regulators for atebimetinib throughout 2024 and 2025.
  • Paused internal work on envometinib in April 2025 to focus resources and funding on the lead pancreatic cancer program.

What Makes Their Science Different

The company uses a unique deep cyclic approach that hits cancer pathways in bursts to reduce toxic side effects on healthy tissue. Its platform combines advanced biological software with 3D tumor models to better predict how patients will respond to treatment.

The Latest Financial Pulse

  • Revenue remained at $0 for the fiscal year ended December 31, 2025.
  • Net loss narrowed to $11.6 million in Q4 2025, a 35.9% improvement from the same period in 2024.
  • Operating income reached negative $13.8 million in Q4 2025, narrowing 25.9% year-over-year.
  • Free cash flow hit negative $10 million in Q4 2025, which was a 31.4% improvement from the previous year.

The Path Forward

Immuneering has evolved from a data services provider into a clinical-stage drug developer. The company is now concentrating its efforts on starting a Phase 3 trial for its lead pancreatic cancer treatment in 2026.

AI Generated • May 12, 2026

Industry

Biotechnology

Sector

Health Care

Employees

55

CEO

Benjamin J. Zeskind, PhD, MBA

Website

www.immuneering.com

Headquarters

Cambridge, MA 02142, US

IMRX Financials

Key Financial Metrics (TTM)

Gross Margin

-169.75%

Operating Margin

-5276202.90%

Net Income Margin

-15867.83%

Return on Equity

-0.11%

Return on Capital

-26.71%

Return on Assets

-28.35%

Earnings Yield

-26.53%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$284.02MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

64.70M

Volume

768.57K

Avg. Volume

1.49M

Financials (TTM)

Gross Profit

-$612.73K

Operating Income

-$19.04B

EBITDA

-$63.37M

Operating Cash Flow

-$34.96B

Capital Expenditure

-$107.43M

Free Cash Flow

-$35.06B

Cash & ST Invst.

$149.90M

Total Debt

$3.63M

Immuneering Performance Analysis

Immuneering annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 316,952-84.8%
20232023-12-31USD 0N/A
20242024-12-31USD 0N/A
20252025-12-31USD 0N/A
Immuneering sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30N/A
Q42025-12-31N/A
Q12026-03-31N/A
Q22026-06-30N/A
Immuneering annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -1.9150.3%
20232023-12-31USD -1.88-1.7%
20242024-12-31USD -2.048.2%
20252025-12-31USD -1.27-37.5%
Immuneering sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-305.0%
Q42025-12-3152.6%
Q12026-03-31-16.7%
Q22026-06-30-28.6%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$360.96K

N/A

Gross Profit

$180.48K

N/A

Gross Margin

50.00%

N/A

Market Cap

$284.02MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$7.68M

N/A

Employees

37

N/A

Net Income

-$17.27M

-19.7%

EBITDA

-$19.18M

-30.8%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$149.90M

+468.8%

Total Debt

$3.63M

-9.2%

Accounts Receivable

$3.38M

N/A

Inventory

$0.00

N/A

Long Term Debt

$3.20M

-11.8%

Short Term Debt

$428.96K

+16.9%

Return on Assets

-28.35%

N/A

Return on Invested Capital

-98.20%

N/A

Free Cash Flow

-$35.02B

-370589.4%

Operating Cash Flow

-$34.92B

-369537.4%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
TRDAEntrada Therapeutics, Inc.
$6.87-2.69%
FHTXFoghorn Therapeutics Inc.
$5.57+14.14%
PYXSPyxis Oncology, Inc.
$3.75+19.81%
ENTAEnanta Pharmaceuticals, Inc.
$13.34+0.91%

Trending Stocks

Symbol / CompanyPricePrice Chg
SPCXSpace Exploration Technologies
$114.92+0.06%
NVDANvidia
$218.99-0.00%
TTDThe Trade Desk
$17.67-0.07%
SOUNSoundHound AI
$7.08+0.10%

Questions About IMRX

What is the current price of Immuneering?

Immuneering is trading at $4.46 per share.

What is the 52-week range for Immuneering?

Over the past 52 weeks, Immuneering has traded between $2.90 and $10.08.

How much debt does Immuneering have?

As of the most recent reporting period, Immuneering reported total debt of $3.73M.

How much cash does Immuneering have on hand?

Immuneering reported $47.32M in cash and cash equivalents in its most recent financial results.

What is Immuneering’s dividend yield?

Immuneering does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services